Glaucoma is a progressive eye disorder characterized by fluid buildup inside the eye, causing ocular hypertension. By 2040, it is estimated that 111.8 ...

A 14-year-old patient presented to the ED with a 12-month history of joint pains and a 2-month history of headaches and ...

Bimatoprost is under clinical development by Laboratoires Thea and currently in Phase III for Ocular Hypertension.

H-1337 is under clinical development by D. Western Therapeutics Institute and currently in Phase II for Open-Angle Glaucoma.

Some patients with ocular hypertension who develop primary open angle glaucoma experience rapid visual field loss.

Our purpose is to update the comprehensive ophthalmologist about the results of the Ocular Hypertension Treatment Study and the current clinical management of ocular hypertension. In the Ocular ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

Purpose: To review the literature regarding ocular hypertension following intravitreal antivascular endothelial growth factor therapy, and to propose a novel mechanism for the development of ...

Retina, choroid and vitreous hemorrhages and vascular disorders; 9. Ocular sensory symptoms NEC; 10. Ocular injuries; 11. Glaucoma and ocular hypertension; 12. Ocular neoplasms. Based on the results ...

and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical ...

Ocular Therapeutix, Inc ... in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow Ocular on its website, LinkedIn or X. The Ocular Therapeutix ...